Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer: An International, Multicenter, Randomized Phase III Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03921996
• Other study ID #: SAKK 09/18
• Status: Terminated
• Phase: Phase 3
• Start date: August 27, 2019
• Est. completion date: November 11, 2021

Study information

• Verified date: March 2023
• Source: Swiss Group for Clinical Cancer Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

For patients with intermediate-risk prostate cancer plus a predicted risk of >5% for positive lymph nodes and with high-risk prostate cancer, international guidelines recommend ePLND along with the RP. Besides an improved accuracy in staging, the therapeutic role of ePLND remains controversial. We hypothesize that ePLND prolongs time to biochemical recurrence (BCR) and prostate cancer-specific survival (PCSS) in intermediate- and high-risk PCa patients.

Description:

Radical prostatectomy (RP) is the surgical standard treatment for men with localized prostate cancer (PCa) and a life expectancy of > 10 years. RP is a treatment option for localized PCa that shows benefit in prostate cancer-specific survival (PCSS) and overall survival compared to conservative management. According to the guideline recommendations of the European Association of Urology (EAU), RP should be accompanied by extended pelvic lymph node dissection (ePLND) in patients with intermediate-risk PCa (D'Amico classification) and > 5% nomogram (Briganti) predicted risk of positive lymph nodes and in all high-risk PCa cases.

Besides an improved accuracy in staging, the therapeutic role of ePLND remains controversial. The primary goal of this trial is to provide high-level evidence regarding the therapeutic benefit of ePLND in intermediate- and high-risk PCa patients without clinical evidence of nodal involvement. It is hypothesized that ePLND prolongs time to biochemical recurrence (BCR) and prostate cancer-specific survival (PCSS) in intermediate- and high-risk PCa patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 57
• Est. completion date: November 11, 2021
• Est. primary completion date: November 11, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures.

• Histologically proven localized adenocarcinoma of the prostate.

• High-risk prostate cancer or intermediate-risk prostate cancer defined by D'Amico classification system, with an estimated risk of >5% of lymph node metastasis.

• Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence.

• Age = 18 years and = 80 years.

• WHO performance status 0-1.

• Adequate condition (ASA = III) for general anesthesia and radical prostatectomy surgery.

• Baseline Quality of Life (QoL) questionnaires have been completed.

Exclusion criteria

• Any pre-operative evidence for T4 disease.

• Metastatic prostate cancer according to staging or evidence of lymph node metastasis by imaging, defined as any pelvic lymph node >9 mm in the short axis or positive lymph nodes detected by imaging techniques with sensitivities similar or better than PSMA-PET or Choline-PET prior to surgery.

• PSA = 50 ng/ml.

• Any prior neo-adjuvant, local or systemic treatment for prostate cancer (alpha reductase inhibitors for treatment of benign hyperplasia are allowed)

• Previous pelvic lymph node dissection.

• Any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment.

• Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Procedure:
• Radical prostatectomy (RP) followed by ePLND
ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
• Radical prostatectomy (RP) only
Radical prostatectomy

Locations

Country	Name	City	State
Switzerland	Kantonsspital Aarau AG	Aarau
Switzerland	Universitätsspital Basel	Basel
Switzerland	Inselspital, Bern	Bern
Switzerland	Kantonsspital Graubuenden	Chur
Switzerland	Hôpitaux Universitaires Genève	Genève
Switzerland	Kantonsspital Baselland	Liestal
Switzerland	Luzerner Kantonsspital	Luzern
Switzerland	Spital Thurgau AG (Frauenfeld and Münsterlingen)	Münsterlingen
Switzerland	Kantonsspital St. Gallen	St. Gallen
Switzerland	Stadtspital Triemli	Zürich
Switzerland	Universitätsspital Zürich	Zürich

Sponsors (1)

Lead Sponsor	Collaborator
Swiss Group for Clinical Cancer Research

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to biochemical recurrence (BCR)	The primary endpoint of this trial is time to BCR, defined as time from randomization to biochemical recurrence, defined as serum PSA level = 0.2 ng/ml, with a second confirmatory serum PSA level = 0.2 ng/ml. Patients not experiencing an event will be censored at the date of the last available assessment or at the start of adjuvant or salvage treatment, if any.	From the date of randomization until the date of biochemical recurrence, assessed up to 15 years after surgery
Secondary	Prostate-specific antigen (PSA) persistence	PSA persistence is defined as failure to reach a PSA value of <0.1 ng/ml within 12 weeks (+ 2 weeks) postoperatively.; Patients with no assessments within the first 12 weeks (+ 2 weeks) after surgery will be counted as failures for this endpoint	From the date of surgery to 14 weeks after surgery
Secondary	Time to initiation of adjuvant or salvage therapies	Time to initiation of adjuvant or salvage therapies will be calculated as the time from randomization to the start of any type of adjuvant or salvage therapy. Patients not starting adjuvant or salvage therapies are censored at the last date they were known to be alive.	From the date of randomization until the date of start of any type of adjuvant or salvage therapy, assessed up to 15 years after surgery
Secondary	Time to loco-regional recurrence	Time to loco-regional recurrence will be calculated from randomization until local (prostate bed) or regional (extent of ePLND template) recurrence, whichever occurs first. Patients not experiencing an event will be censored at the date of the last available assessment or at the start of adjuvant or salvage therapy, if any.	From the date of randomization until the date of local or regional recurrence, assessed up to 15 years after surgery
Secondary	Time to distant metastasis	Time to distant metastasis will be calculated from randomization until first occurrence of distant metastasis. Patients not experiencing an event will be censored at the date of the last available assessment.	From the date of randomization until the date of first occurrence of distant metastasis, assessed up to 15 years after surgery
Secondary	Prostate cancer-specific survival (PCSS)	PCSS will be calculated as the time from randomization to the date of death due to prostate cancer. Patients who died due to other reasons will be censored at the time of death. All other patients will be censored at the last date they were known to be alive.; Causes of death may require critical review by the coordinating investigator and the medical advisor. Particular attention will be paid to men who have been reported as having died from prostate cancer without previously reported progression or recurrence and men who were reported as having died from non-prostate cancer causes after developing biochemical or clinical progression.	From the date of randomization until the date of death due to prostate cancer, assessed up to 15 years after surgery
Secondary	Overall survival (OS)	OS will be calculated from randomization until death from any cause. Patients not experiencing an event will be censored at the last date they were known to be alive.	From the date of randomization until the date of death, assessed up to 15 years after surgery
Secondary	Intraoperative complications	Intraoperative complications will be assessed using the CLASSIC system.	During surgery
Secondary	Postoperative complications	Postoperative complications will be assessed using the Clavien-Dindo classification.	From the date of surgery to 14 weeks after surgery
Secondary	Adverse events (AE)	AEs will be assessed according to NCI CTCAE v5.0.	From the date of registration to 15 years after surgery